Amunix

Mountain View, United States Founded: 2006 • Age: 20 yrs Acquired By Sanofi
Peptide-based therapeutics are developed for cancers and immune disorders.
Request Access

About Amunix

Amunix is a company based in Mountain View (United States) founded in 2006 was acquired by Sanofi in December 2021.. Amunix has raised $200.59 million across 9 funding rounds from investors including BlackRock, Bain Capital and Franklin Templeton. The company has 82 employees as of December 31, 2021. Amunix operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Biogen, among others.

  • Headquarter Mountain View, United States
  • Employees 82 as on 31 Dec, 2021
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Amunix Operating Inc.
Operational Areas
Healthcare → Healthcare Products & Supplies
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $200.59 M (USD)

    in 9 rounds

  • Latest Funding Round
    $117 M (USD), Series B

    Mar 04, 2021

  • Investors
    BlackRock

    & 18 more

  • Employee Count
    82

    as on Dec 31, 2021

  • Acquired by
    Sanofi

    (Dec 20, 2021)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal
People of Amunix
Headcount 50-200
Employee Profiles 43
Employee Profiles
People
Bianca Reyes
Research Associate, Bioanalytical Sciences
People
Caitlin Exton (Considine)
Research Associate II
People
Enrico Paul Payson
Research Associate III
People
Tracy Young, PhD
Director, Protein Engineering

Unlock access to complete

Funding Insights of Amunix

Amunix has successfully raised a total of $200.59M across 9 strategic funding rounds. The most recent funding activity was a Series B round of $117 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 9
  • Last Round Series B — $117.0M
  • First Round

    (15 Apr 2007)

  • Investors Count 18
Date Amount Transaction Name Valuation Lead Investors Investors
Mar, 2021 Amount Series B - Amunix Valuation Viking Global Investors
Mar, 2020 Amount Series A - Amunix Valuation Omega Funds
Jun, 2018 Amount Series A - Amunix Valuation Frazier Healthcare Partners
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Amunix

Amunix has secured backing from 19 investors, including venture fund and institutional investors. Prominent investors backing the company include BlackRock, Bain Capital and Franklin Templeton. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Private investment firm focused on multiple sectors
Founded Year Domain Location
Debt and equity investments are pursued across multiple sectors.
Founded Year Domain Location
Multiple sectors are targeted for venture capital investments.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Amunix

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Amunix

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Amunix Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Amunix

Amunix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Biogen, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
mRNA-based therapeutics for diseases including cancer and infections are developed.
domain founded_year HQ Location
Novel biopharmaceutical medicines are developed for unmet medical needs.
domain founded_year HQ Location
Targeted and immune-oncology drugs for cancer treatment are developed.
domain founded_year HQ Location
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
domain founded_year HQ Location
Therapies for neurodegenerative and immunology disorders are developed.
domain founded_year HQ Location
Small molecules are developed for cancer and skin disease treatments.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Amunix

Frequently Asked Questions about Amunix

When was Amunix founded?

Amunix was founded in 2006 and raised its 1st funding round 1 year after it was founded.

Where is Amunix located?

Amunix is headquartered in Mountain View, United States. It is registered at Mountain View, California, United States.

Is Amunix a funded company?

Amunix is a funded company, having raised a total of $200.59M across 9 funding rounds to date.

How many employees does Amunix have?

As of Dec 31, 2021, the latest employee count at Amunix is 82.

What does Amunix do?

Developer of peptide-based therapeutics. The lead candidate AMX-818 is a masked T cell engager targeting HER2, a receptor tyrosine kinase expressed on a wide variety of solid tumors, others include Wave2 XPAT, Wve3 XPAT, IL12 XPAC, and others for immune disorders and cancers. The companys products are based on its proprietary XTEN half-life extension, XDC drug-conjugate delivery, and ProTIA pro-drug, bispecific T cell engager platform.

Who are the top competitors of Amunix?

Amunix's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.

Who are Amunix's investors?

Amunix has 19 investors. Key investors include BlackRock, Bain Capital, Franklin Templeton, Sanofi, and HHS.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available